AGC
BMRN icon

Angelo Gordon & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Angelo Gordon & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,300
Closed -$660K – 73
2014
Q4 		$660K Sell
7,300
-14,400
-66% -$1.2M 0.03% 69
2014
Q3 		$1.57M Buy
+21,700
New +$1.43M 0.1% 70

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Angelo Gordon & Co's BMRN Position: Q1 2015 in Review

Angelo Gordon & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 7,300 shares — an estimated $660K sold.

Angelo Gordon & Co first reported a position in BMRN in Q3 2014 and held it in 2 quarters. The position peaked at $1.57M in Q3 2014. 378 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

  • Angelo Gordon & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Angelo Gordon & Co sold 7,300 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $660K.
  • Angelo Gordon & Co first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Angelo Gordon & Co's BioMarin Pharmaceuticals position peaked at $1.57M in Q3 2014.
  • 378 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Angelo Gordon & Co's 13F filing for Q1 2015, filed 15 May 2015.